Topiramate

🧮 Dose calculator

Migraine prophylaxis · Regimen source: FDA Topiramate · 2.3, Table 3

• • Weekly titration: week 1: 25 mg evening only; week 2: 25 am + 25 pm; week 3: 25 am + 50 pm; week 4: 50 + 50 (100 mg/day). Do not break tablets (bitter). FDA Topiramate · 2.3, Table 3FDA Topiramate · 2.4

Enter age (weight is optional for this regimen).

👥 Special populations

• 🤰 PregnancyDangerous / avoid

  Label: can cause fetal harm. Dangerous in pregnancy. FDA Topiramate · 8.1

  “Risk Summary Topiramate can cause fetal harm when administered to a pregnant woman.”

• 🤱 BreastfeedingUse with caution

  Label: use with caution while breastfeeding; see the label text. FDA Topiramate · 8.2

  “Risk Summary Topiramate is excreted in human milk [see Data].”

• 👶 ChildrenUse with caution

  The label has conditions, age limits or notes for children; the label sentence is quoted below. FDA Topiramate · 8.4

  “Adjunctive Treatment for Epilepsy Pediatric Patients 2 Years of Age and Older The safety and effectiveness of topiramate as adjunctive therapy for the treatment of partial-onset seizures, primary generalized tonic-clonic seizures, or seizures associated with Lennox-Gastaut syndrome have been established in pediatric …”

• 👴 Older adultsUse with caution

  Label: use with caution in older adults, usually starting at the low end of the dose range. FDA Topiramate · 8.5

  “Dosage adjustment may be necessary for elderly with age-related renal impairment (creatinine clearance rate < 70 mL/min/1.73 m 2 ) resulting in reduced clearance [see Dosage and Administration ( 2.5 ), Clinical Pharmacology ( 12.3 )] .”

• ⚥ Females & males of reproductive potentialUse with caution

  Label has advice on pregnancy testing, contraception or fertility for females and males. FDA Topiramate · 8.3

  “Contraception Women of childbearing potential who are not planning a pregnancy should use effective contraception because of the risk of major congenital malformations, including oral clefts and the risk of infants being SGA [see Drug Interactions ( 7.4 ) and Use in Specific Populations ( 8.1 )] .”